Why use it

Unlike the COMM (which assesses current misuse) and ORT/SOAPP-R (which predict baseline misuse risk), the DIRE uniquely integrates both the clinical suitability of opioid therapy for the pain condition AND the patient's psychosocial risk profile into a single candidacy score. This makes it valuable in primary care and pain clinic settings for initial opioid prescription decisions and for structuring opioid treatment agreements.

About

The DIRE (Diagnosis, Intractability, Risk, Efficacy) Score is a clinician-administered tool developed by Belgrade and colleagues to predict patient compliance and efficacy of long-term opioid therapy in patients with chronic non-cancer pain. Published in 2006, the DIRE evaluates four domains: (D) Diagnosis — the nature and expected severity of the underlying pain condition; (I) Intractability — the adequacy of previous non-opioid pain management attempts; (R) Risk — four sub-categories assessing psychological, chemical health, reliability, and social support risk factors; (E) Efficacy — functional improvement anticipated or observed on opioid therapy. Each domain is scored 1–3, with the Risk domain comprising four independently scored subscores (R1–R4), each 1–3. The total score ranges from 7 to 21. Scores ≥ 14 predict good opioid treatment candidacy. The DIRE is used as a pre-therapy risk stratification tool, complementing other tools such as the ORT (Opioid Risk Tool) and SOAPP-R.

When to use

Before initiating long-term opioid therapy for chronic non-cancer pain in a new patient
When considering escalating opioid dose or transitioning to stronger opioids
As part of a comprehensive pre-opioid assessment alongside PDMP review, urine drug screen, and ORT
Re-evaluating candidacy after a significant change in the patient's psychosocial circumstances
Multidisciplinary pain team case reviews to standardize prescribing decisions

Formula

DIRE = D + I + R1 + R2 + R3 + R4 + E (each domain scored 1–3) Total: 7–21 D — Diagnosis (nature of pain condition): 1 = Benign chronic condition, low medical need; 2 = Progressive or stable condition, moderate need; 3 = Progressive disease with severe pain or life-limiting diagnosis I — Intractability (prior treatment history): 1 = Few therapies tried, patient passive; 2 = Adequate trials but barriers prevent optimal non-opioid care; 3 = Most appropriate non-opioid therapies fully tried R1 — Psychological Risk: 1 = Serious active mental health condition affecting pain management; 2 = Minor stable condition; 3 = No mental health condition or no impact R2 — Chemical Health Risk: 1 = Active illicit drug use, prescription abuse, or serious alcohol problem; 2 = Family or remote personal hx of substance use; 3 = No personal or family history of substance abuse R3 — Reliability: 1 = Serious issues (multiple lost Rx, multiple abnormal UDS, non-attendance); 2 = Minor issues; 3 = Highly reliable patient R4 — Social Support: 1 = Chaotic living situation, isolated; 2 = Limited support; 3 = Good social support E — Efficacy: 1 = Poor functional improvement expected or observed; 2 = Moderate functional improvement; 3 = Significant functional improvement Interpretation: ≥ 14: Good candidate 8–13: Moderate candidate 7: Poor candidate

Pearls & pitfalls

The DIRE is a CLINICIAN-scored tool — unlike ORT or SOAPP-R, it requires clinician judgment and is not self-administered by the patient.
The Risk (R) domain is scored across four independent subscores (R1: Psychological, R2: Chemical health, R3: Reliability, R4: Social support) — each rated 1–3. A low score in any single R sub-domain warrants targeted intervention.
A history of substance use disorder (chemical health risk, R2 = 1) substantially lowers the DIRE score — this does NOT mean opioids are absolutely contraindicated but signals need for much closer monitoring, potentially with addiction medicine co-management.
The Efficacy (E) sub-score requires some clinical knowledge of how the patient's specific condition is likely to respond to opioids — pure neuropathic pain (e.g., post-herpetic neuralgia) may score lower than musculoskeletal pain.
The DIRE should always be used in conjunction with other tools and clinical judgment — no single tool should be the sole basis for denying or initiating opioid therapy.
Documentation of the DIRE score in the medical record supports shared decision-making and provides a defensible clinical rationale for prescribing decisions.
The DIRE does NOT replace a full pain evaluation, functional assessment, or DSM-5 substance use disorder evaluation — these should be completed in high-risk patients.
A DIRE ≥ 14 predicts good candidacy but does NOT guarantee absence of misuse — ongoing monitoring with COMM, UDS, and PDMP remains essential.

Next steps

DIRE ≥ 14 (Good Candidate): Opioid therapy is likely to be safe and effective. Proceed with opioid treatment agreement, monitoring plan (UDS, PDMP, COMM), and follow-up schedule. DIRE 8–13 (Moderate Candidate): Proceed with caution. Address modifiable risk factors before initiating opioids. Structured monitoring plan essential. Consider referral to addiction medicine or behavioral health for co-management. DIRE ≤ 7 (Poor Candidate): Long-term opioid therapy not recommended. Address underlying risks first. Optimize non-opioid therapies. Strongly consider multidisciplinary pain management referral. If opioids are initiated despite low score, extreme vigilance and frequent monitoring required.

Evidence

Belgrade MJ et al. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681. PMID:16942948. Prospective study of 61 patients on long-term opioid therapy. The DIRE score predicted compliance (AUC 0.86, p<0.001) and efficacy (AUC 0.80, p<0.001) of opioid therapy. Sensitivity 94%, specificity 87% for identifying good candidates at threshold ≥ 14.

References

Belgrade MJ et al. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681. — link
Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130. — link
Dowell D et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. — link

DIRE Score for Opioid Treatment

Calculator